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Abstract
Background and Objectives: To weight ischemic and bleeding events according to their severity to be used in a composite
outcome in RCTs in the field of thrombosis prevention.
Method: Using a Delphi consensus method, a panel of anaesthesiology and cardiology experts rated the severity of
thrombotic and bleeding clinical events. The ratings were expressed on a 10-point scale. The median and quartiles of the
ratings of each item were returned to the experts. Then, the panel members evaluated the events a second time with
knowledge of the group responses from the first round. Cronbach’s a was used as a measure of homogeneity for the
ratings. The final rating for each event corresponded to the median rating obtained at the last Delphi round.
Results: Of 70 experts invited, 32 (46%) accepted to participate. Consensus was reached at the second round as indicated by
Cronbach’s a value (0.99 (95% CI 0.98-1.00)) so the Delphi was stopped. Severity ranged from under-popliteal venous
thrombosis (median=3, Q1=2; Q3=3) to ischemic stroke or intracerebral hemorrhage with severe disability at 7 days and
massive pulmonary embolism (median=9, Q1=9; Q3=9). Ratings did not differ according to the medical specialty of
experts.
Conclusions: These ratings could be used to weight ischemic and bleeding events of various severity comprising a
composite outcome in the field of thrombosis prevention.
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Introduction
A composite outcome consists of two or more component
outcomes. Patients who have experienced any one of the events
specified by the components are considered to have experienced
the composite outcome[1,2]. The use of composite outcomes in
RCTs is common, particularly in cardiology[3] having the
advantage of reducing sample size requirement, costs and time
because of higher event rates. Composite outcomes estimate the
net clinical benefit of treatment and enable to avoid an arbitrary
choice between a number of important outcomes[2,4–7] so they
may be used to summarize the risk/benefit profile of an
intervention[8,9]. In the field of thrombosis prevention where
treatments aim to decrease the rate of ischemic events but may
cause hemorrhagic side effects of various severity, using composite
outcomes including both ischemic and hemorrhagic events may be
particularly appropriate to capture the net clinical benefit. Many
authors have argued that all components of a composite outcome
should be of similar importance to adequately interpret treatment
effect[1–4,6–8,10–12] which is not frequently the case. Cordoba
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70% of RCTs reporting a binary composite outcome[1]. Choosing
individual components of the same importance might also be
irrelevant if the aim is to capture the overall impact of treatment.
This is why some authors have proposed to assign each component
a weight reflecting severity[8,12–14]. Since weighting may
be somewhat arbitrary, it should be subjected to consensus
panel[12,13,15].
STRATAGEM is a multicenter, randomized, double-blind,
placebo-controlled trial whose objective was to compare low-dose
aspirin therapy versus placebo (stopping anti platelet therapy) in
the perioperative period in patients treated with antiplatelet
therapy as secondary prevention (with documented symptomatic
stable atherothrombotic disease) who undergo non-coronary
surgery (registration number: NCT00190307, IRB authorization
from the ‘‘Comite ´ Consultatif de Protection des Personnes se
pre ˆtant a ` la Recherche Biome ´dicale (CCPPRB) de Paris Bichat’’
(Ref 2004/18, authorization obtained the 10th of Novembre
2004). The composite outcome took into account the balance of
risk and benefit associated with maintaining antiplatelet therapy in
the peri-operative period including both ischemic events (e.g.,
ischemic stroke, non-fatal myocardial infarction, acute limb
ischemia, clinical deep venous thrombosis) and bleeding events
(e.g., life-threatening bleeding or conducive to revision, or redo
surgery, cerebral hemorrhage, intra- or retroperitoneal bleeding,
bleeding requiring the transfusion of more than 3 units of packed
red blood cells) in addition to overall mortality within one month
following surgery. Since the individual components of this
composite outcome clearly do not have the same value and
severity, the aim of the present project was to attribute consensus-
driven weights to ischemic and bleeding events according to their




The Delphi method was used to synthesize expert opinion
[16,17]. It is a well-recognized method to reach consensus, relying
on the following principles: anonymity, iteration, controlled
feedback, and statistical aggregation of group responses [18–20].
Staff
A steering committee was initiated to perform this study and
included all authors. The committee was responsible for the
selection of events to be evaluated and experts, the analysis of the
responses and the presentation of results.
Selection of experts
Experts were recruited from clinical disciplines involved in the
management of patients with atherothrombotic disease in the
perioperative period. In France, both cardiologists and anesthe-
siologists are involved in this field. Experienced academic experts
were identified from different centers all over the country within
national organizations such as the French Society of Anesthesia
and Intensive Care or the French Society of Cardiology. The
selected experts had also to be involved in design, execution and
evaluation of clinical trials. Thirty cardiologists and 40 anaesthe-
siologists were invited to participate in the study. The experts were
sent a standardized information package containing a synopsis of
the study and a description of the Delphi process. The experts
were informed that the consensus-driven ratings would be used as
weights in a composite outcome.
Selection of events to be evaluated
Events to be evaluated were identified from the Common
Terminology Criteria for Adverse Events (CTCAE) v3.0[21]
which is a descriptive terminology that can be used for Adverse
Event (AE) reporting. A grading (severity) scale is provided for
each AE term. One author (F.T.) identified 28 ischemic and
bleeding events that were then submitted to the steering committee
for validation to enter the first Delphi round. They covered all the
fields addressed by the STRATAGEM composite endpoint, in a
more detailed way (for instance myocardial infarction was
addressed by 3 different events corresponding to 3 different levels
of severity in accordance with the CTCAE). We did not include
death among the events to be assessed since the steering committee
decided to attribute it automatically the worse rating (i.e., 10). The
items involved in the Delphi process are reported in table 1.
Delphi consensus
The steering committee planned to perform at least two Delphi
rounds. If consensus was not reached after 2 rounds, it was
planned to perform additional rounds until a consensus was
reached. The consensus process was conducted via email. Two
reminders were sent at each round in case of non response.
In the first Delphi round, each member of the panel evaluated
the severity of each of the 28 events on a 10-point scale. For each
event, the experts were asked to answer the following question:
‘‘According to you, how severe is this event?’’. A 10-point scale
with the anchors ‘‘not severe at all’’ at 0 and ‘‘extremely severe’’ at
9 was used to record the responses. The experts had the possibility
to suggest events that were missing. They were added at the
following round provided that they were not redundant with the
other events. The median rating (1
st quartile-3
rd quartile (Q1–Q3))
for the whole group was established for each individual event.
In the second round, the experts considered the same event, and
were also informed of each event rating at the first round by
reporting of the median ((Q1–Q3)) rating on the scale for each
event. The experts were asked to rate each event again in light of
the responses at the first round.
Analysis
For each event, the experts’ ratings were summarized as median
(Q1–Q3). We applied a Last Observation Carried Forward
(LOCF) strategy for missing data after the first round that is to
say that, if an expert did not answer the second round, we
considered his answers at the first round.
The concept of consensus within a group was defined as
homogeneity or consistency opinion among the experts. Assuming
that each event was characterized by a constant but unknown
severity, the ratings of the experts could be considered as multiple
measures of this characteristic. We used Cronbach’s a to measure
internal consistency among the experts for the set of events reflects
the extent of consensus within the group for the severity of the set
of events. When Cronbach’s a is close to 1.0, it can be argued that
there is consistency in the responses of the index panel, suggesting
consensus. According to the recommendation of Bland and
Altman [22], we considered that a consensus would be reached
for a Cronbach’s a value of 0.95. We also calculated intra-class
correlation coefficient as a measure of the overall agreement
between experts [23]. Ninety five percent confidence intervals for
both Cronbach’s a and intra-class correlation coefficient were
calculated with bootstraps (1000 simulations). We planned to stop
the Delphi consensus after the second round if the Cronbach’s a
value was superior to 0.95. The final weight for each event was the
median rating obtained at the last Delphi round.
All analyses were performed on R version 2.10.0[24].
Weights for Composite Outcome in Thrombosis RCT
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Delphi process
Of the 70 experts invited (30 cardiologists and 40
anaesthesiologists), 32 (46%) accepted to participate in the
survey and completed the first round (9 cardiologists (30%) and
23 anesthesiologists (57%)). Twenty five experts (78%)
completed the second round (6 cardiologists and 19 anesthe-
siologists). One event suggested by an expert was added at the
second round.
At the second round, Cronbach’s a was 0.99 (95% CI 0.98–
1.00) showing a high internal consistency indicating consensus
between the experts and therefore the end of the Delphi process.
Overall agreement between experts was good with an intra-class
correlation coefficient at 0.72 (95% CI: 0.59–0.80).
Consensus
A summary of experts’ rating for each event and for each Delphi
round is presented in Table 2. The ranking of the events slightly
changed between the 1
st and 2
nd round. Events with the lowest
rating of severity were: increased Troponin level (median=3,
Q1=3; Q3=4) and infra-popliteal venous thrombosis (medi-
an=3, Q1=2; Q3=3). Events with the highest rating of
importance were: ischemic stroke with severe disability at 7 days
(median=9, Q1=9; Q3=9), non-fatal myocardial infarction with
heart failure (median=9, Q1=8; Q3=9), massive pulmonary
embolism (median=9, Q1=9; Q3=9) and intra-cerebral hem-
orrhage with severe disability at 7 days (median=9, Q1=9;
Q3=9). Delphi-consensus weights are presented in Table 3.
Ratings did not differ according to the specialty of experts
(Appendix S1). Ratings at the first Delphi round did not differ
Table 1. Delphi panel events.
Clinical events Definition
Ischemic events
Transient ischemic attack Transient ischemic event q 24 hrs duration
Ischemic stroke with no symptom at 7 days Defined by a modified Rankin scale of 0–1
Ischemic stroke with slight disability at 7 days Defined by a modified Rankin scale of 2
Ischemic stroke with moderate disability at 7 days Defined by a modified Rankin scale of 3
Ischemic stroke with severe disability at 7 days Defined by a modified Rankin scale of 4–5
Limb ischemia not requiring heparin or intervention Brief (q 24 hrs) episode of ischemia managed non surgically and without
permanent deficit
Limb ischemia requiring heparin or intervention Recurring or prolonged (. 24 hrs) requiring medical or surgical intervention
Limb ischemia requiring amputation* Life-threatening, disabling limb ischemia requiring end organ damage
(i.e., limb loss)
Increased level of troponin Without new Q wave or heart failure
Non-fatal myocardial infarction without heart failure Killip 1
Non-fatal myocardial infarction with heart failure Killip $2
Under-popliteal deep venous thrombosis Under-popliteal deep venous thrombosis
Deep venous thrombosis with iliac extension Deep venous thrombosis with iliac extension
Venous thrombosis of the pectoral limb Venous thrombosis of the pectoral limb
Venous thrombosis other Venous thrombosis other
Pulmonary embolism Pulmonary embolism
Massive pulmonary embolism Clinical or echographical acute pulmonary heart and/or impact on hepatic
biology and/or more than half obstruction at angiography
Hemorrhagic events
Intracerebral hemorrhage with no symptom at 7 days Defined by a modified Rankin scale of 0–1
Intracerebral hemorrhage with slight disability at 7 days Defined by a modified Rankin scale of 2
Intracerebral hemorrhage with moderate disability at 7 days Defined by a modified Rankin scale of 3
Intracerebral hemorrhage with severe disability at 7 days Defined by a modified Rankin scale of 4–5
Bleeding with increased length of stay Mild bleeding not requiring intervention other than iron supplements
Bleeding requiring redo surgery or endoscopic sclerosis
Bleeding requiring both redo surgery and interventions to maintain
cardiac output
Bleeding with life-threatening consequences requiring urgent and major
interventions
Bleeding requiring transfusion of 3 U or more packed red blood cells Bleeding requiring transfusion of 3 U or more packed red blood cells
Bleeding requiring both transfusion of 3 U or more packed red blood cells
and interventions to increase cardiac output
Bleeding with life-threatening consequences requiring urgent and major
interventions
Intra or retroperitoneal bleeding Intra or retroperitoneal bleeding
Intra or retroperitoneal bleeding requiring interventions to maintain cardiac
output
Bleeding with life-threatening consequences requiring urgent and major
interventions
Mesenteric ischaemia is considered as peripheral ischemia and then classified as ‘‘Life-threatening, disabling limb ischemia requiring end organ damage (i.e., limb loss)’’
and thus with limb ischemia requiring amputation.
doi:10.1371/journal.pone.0018461.t001
Weights for Composite Outcome in Thrombosis RCT
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those who did not respond (Appendix S2).
Discussion
Before introducing a new treatment or strategy to common
practice, or in comparative effectiveness research, capturing the
overall impact of a therapeutic strategy in term of benefit and risk
is important[25]. This is a well-recognized advantage of composite
outcomes, but their use relies on the underlying assumption that
patients will attach similar importance to each component [5].
However, this is rarely true. As outlined by Ferreira-Gonzalez[4]
and cordoba[1], most composite end points showed either a large
or moderate gradient in importance to patients. Weighting
composite outcomes according to severity or importance to
patients has been suggested to deal with this issue[8,12–14]. This
approach is possible only if a consensus can be reached on the
importance of each individual component[15]. We report in this
study how consensus-driven severity ratings were obtained for a
wide range of ischemic and bleeding events comprising a
composite outcome. The Delphi method was used to assign each
individual component of the composite outcome a rating reflecting
its severity. This well-recognized method to reach consensus in
Table 2. Summary of experts’ rating at each Delphi round for
the assessment of severity on a 10-point scale of events














Transcient ischemic attack 5 (3–6) 5 (4–5)
Ischemic stroke with no symptom at 7 days 6 (5–6) 6 (5–6)
Ischemic stroke with slight disability at 7 days 7 (6–7) 7 (6–7)
Ischemic stroke with moderate disability at 7 days 8 (7–8) 8 (8–8)
Ischemic stroke with severe disability at 7 days 9 (9–9) 9 (9–9)
Limb ischemia not requiring heparin or
intervention
5 (4–6) 5 (4–5)
Limb ischemia requiring heparin or intervention 7 (6–7) 6 (6–7)
Limb ischemia requiring amputation 9 (8–9) 9 (8–9)
Increased level of troponin 4 (3–5) 4 (3–4)
Non-fatal myocardial infarction without heart
failure
7 (6–8) 7 (6–7)
Non-fatal myocardial infarction with heart failure 8 (8-9) 9 (8–9)
Under-popliteal deep venous thrombosis 3 (2–4) 3 (2–3)
Deep venous thrombosis with iliac extension 6 (5–6) 6 (6–6)
Venous thrombosis of the pectoral limb 5 (4–6) 5 (4–5)
Venous thrombosis other 7 (6–8) 7 (6–7)
Pulmonary embolism 7 (6–8) 8 (7–8)
Massive pulmonary embolism 9 (8–9) 9 (9–9)
Hemorrhagic events:
Intracerebral hemorrhage with no symptom
at 7 days
6 (5–6) 6 (5–6)
Intracerebral hemorrhage with slight
disability at 7 days
7 (7–7) 7 (7–7)
Intracerebral hemorrhage with moderate
disability at 7 days
8 (8–8) 8 (8–8)
Intracerebral hemorrhage with severe
disability at 7 days
9 (9–9) 9 (9–9)
Bleeding with increased length of stay 3 (2–4)
Bleeding requiring redo surgery or endoscopic
sclerosis
5 (4–6) 5 (5–6)
Bleeding requiring both redosurgery and
interventions to maintain cardiac output
7 (6–8) 7 (7–8)
Bleeding requiring transfusion of 3 U or more
packed red blood cells
5 (4–7) 5 (4-6)
Bleeding requiring both transfusion of
3 U or more packed red blood cells and
nterventions to increase cardiac output
7 (6–8) 7 (7–8)
Intra or retroperitoneal bleeding 6 (4–7) 6 (5–7)
Intra or retroperitoneal bleeding requiring
interventions to maintain cardiac output
7 (6–8) 8 (7–8)
doi:10.1371/journal.pone.0018461.t002
Table 3. Delphi-consensus weights for ischemic and bleeding




Ischemic stroke with severe disability at 7 days 9
Limb ischemia requiring amputation 9
Non-fatal myocardial infarction with heart failure 9
Massive pulmonary embolism 9
Intracerebral hemorrhage with severe disability at 7 days 9
Ischemic stroke with moderate disability at 7 days 8
Pulmonary embolism 8
Intracerebral hemorrhage with moderate disability at 7 days 8
Intra or retroperitoneal bleeding requiring interventions to
maintain cardiac output
8
Ischemic stroke with slight disability at 7 days 7
Non-fatal myocardial infarction without heart failure 7
Venous thrombosis other 7
Intracerebral hemorrhage with slight disability at 7 days 7
Bleeding requiring both redosurgery and interventions to
maintain cardiac output
7
Bleeding requiring both transfusion of 3 U or more packed
red blood cells and interventions to increase cardiac output
7
Ischemic stroke with no symptom at 7 days 6
Limb ischemia requiring heparin or intervention 6
Deep venous thrombosis with iliac extension 6
Intracerebral hemorrhage with no symptom at 7 days 6
Intra or retroperitoneal bleeding 6
Transcient ischemic attack 5
Limb ischemia not requiring heparin or intervention 5
Venous thrombosis of the pectoral limb 5
Bleeding requiring redo surgery or endoscopic sclerosis 5
Bleeding requiring transfusion of 3 U or more packed red
blood cells
5
Increased level of troponin 4
Under-popliteal deep venous thrombosis 3
Bleeding with increased length of stay 3
No event 0
doi:10.1371/journal.pone.0018461.t003
Weights for Composite Outcome in Thrombosis RCT
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conducted via mail or email which improves feasibility and lowers
costs and it can be completely anonymous which limits the
influence of a single expert. Experts presented a high level of
agreement so the Delphi was stopped at the second round.
All individual components of the composite outcome were ranked
from the most (i.e., death) to the least severe (i.e., absence of event)
considering the final median rating attributed by the experts for each
event. There are several possibilities to deal with the fact that a single
patient may present several events of interest during the follow-up
period. As proposed by Braunwald[13], the score for each patient
may represent the score of the most serious event encountered by this
patient regardless of the number of events having occurred what we
planned to do in this study. Another possibility could be to use the
sum of the ratings for all outcomes encountered[14]. We believe that
presenting both a transient ischemic attack (weight=5) and increased
level of troponin (weight=4) during the follow-up period is not
equivalent to ischemic stroke with severe disability at 7 days
(weight=9). Furthermore, we believe that death from myocardial
infarction should not account for a higher rating than death from
unknown cause occurring at home, which might also be due to
myocardial infarction. Rating multiple events was not possible in our
study given the number of possible combinations so the consensus
was limited to severity ratings for each event and did not relate to
their combination.
Felker proposed an alternative method[26]: all patients who met
the worst event (i.e., death) during the follow-up would be assigned
the worst ranks, in order to their time to event (e.g., the patient
who died first would have the worst rank, the second patient who
died the second worst rank). Patient not dying during study follow-
up would be evaluated for the second worst endpoint and ranked
above those who died, using the same methodology. Those
patients not experiencing any of the event components during
follow-up would be ranked according to quality of life scores from
baseline to last follow-up. After all study subjects are ranked, the
comparative efficacy of the 2 treatments is evaluated by comparing
the ranks between the 2 groups.
Events rated by the experts to be included in the final composite
outcome can be considered as patient important outcomes (which
was previously defined as death, morbidity or, patient reported
outcomes[27]). Nevertheless, a potential limitation of this study is
the absence of involvement of patients to assess the severity of
clinical events which may be differently perceived than by
physicians. We believed that explaining clearly all events with
their possible consequences to make the judgment of patients
possible would have been difficult.
Whatever the way to use the ratings to build the composite
outcome, there is no evidence that such a composite outcome
represents a clinically meaningful endpoint. A validation study
should be undertaken with comparison of the different strategies
for integrating the ratings. Important questions may be also
raised about which between-arm difference will be relevant, with
implications for interpretation of results and sample size
calculation. Calculating sample size is generally difficult for
composite outcomes since information for the control group may
be available for one or several components separately but rarely
for the overall outcome. The most important problem pertains to
the interpretation of results, which is not intuitive using this
approach. Which between-arm difference for the final composite
outcome corresponds to a clinically relevant difference is an
issue.
It has to be noted that the severity ratings were ordinal and not
true interval so the composite outcome should not theorically be
treated as a continuous variable. We also made the assumption
that the experts not responding at the second round would have
had identical answers in the second round and applied a LOCF
strategy. We compared the ratings at the first round between the
experts having responded at the second round and those who did
not and checked that there was no difference in the ratings
(appendix S2). Third, we made the assumption that cardiologists
and anesthesiologists would be consistent in their ratings, which we
verified by comparing their ratings (appendix S1).
In conclusion, the consensus-driven ratings that were obtained
could be used to weight ischemic and bleeding events of various
severity comprising a composite outcome in the field of thrombosis
prevention. This approach could be reproduced for other types of
treatment and medical areas.
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